CATALYST PHARMACEUTICALS INC (CPRX) Stock Price, Quote, News and Overview
NASDAQ:CPRX - Nasdaq - US14888U1016 - Common Stock - Currency: USD
CPRX Quote, Performance and Key Statistics
CATALYST PHARMACEUTICALS INC
NASDAQ:CPRX (1/28/2025, 5:20:00 PM)
After market: 22.6537 -0.19 (-0.82%)22.84
+0.14 (+0.62%)
The current stock price of CPRX is 22.84 USD. In the past month the price increased by 4.24%. In the past year, price increased by 67.69%.
CPRX Latest News, Press Releases and Analysis
While growth is established for NASDAQ:CPRX, the stock's valuation remains reasonable.
Investors seeking growth at a reasonable cost should explore CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Unlocking the Growth Potential of NASDAQ:CPRX.
Exploring CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX)'s CANSLIM characteristics.
Why NASDAQ:CPRX qualifies as a high growth stock.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) qualifies as a high growth stock.
Exploring the Growth Potential of NASDAQ:CPRX as It Nears a Breakout.
Why CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) Is a Standout High-Growth Stock in a Consolidation Phase.
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies
CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (
CPRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.26 | 308.91B | ||
| AMGN | AMGEN INC | 14.58 | 150.67B | ||
| GILD | GILEAD SCIENCES INC | 21.19 | 116.96B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 864.08 | 113.49B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.11 | 75.42B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.75B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 36.01B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.96B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.13B | ||
| NTRA | NATERA INC | N/A | 22.19B | ||
| BIIB | BIOGEN INC | 8.91 | 21.20B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.33B |
Related stock screener links
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 167 full-time employees. The company went IPO on 2006-11-08. The firm is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The firm is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 167
Company Website: https://catalystpharma.com/
Investor Relations: https://ir.catalystpharma.com/
Phone: 13055292522
CPRX FAQ
What is the stock price of CPRX?
The current stock price of CPRX is 22.84 USD.
What is the symbol for CATALYST PHARMACEUTICALS INC stock?
The exchange symbol of CATALYST PHARMACEUTICALS INC is CPRX and it is listed on the Nasdaq exchange.
On which exchange is CPRX stock listed?
CPRX stock is listed on the Nasdaq exchange.
Is CPRX a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for CPRX, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of CPRX.
Does CPRX stock pay dividends?
CPRX does not pay a dividend.
What is the Price/Earnings (PE) ratio of CPRX?
The PE ratio for CPRX is 19.36. This is based on the reported non-GAAP earnings per share of 1.18 and the current share price of 22.84 USD.
What is the Short Interest ratio of CPRX stock?
The outstanding short interest for CPRX is 5.97% of its float.
CPRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX is one of the better performing stocks in the market, outperforming 89.42% of all stocks.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to CPRX. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues.
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.18. The EPS increased by 63.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.01% | ||
| ROA | 18.5% | ||
| ROE | 21.61% | ||
| Debt/Equity | 0 |
CPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to CPRX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 53.42% and a revenue growth 22.87% for CPRX